Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML).

NCT01961765 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT01961765
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01961765 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML).
Lead sponsor
Massachusetts General Hospital
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2013
Completion date
January 31, 2017
Enrollment
18 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

refractory acute myeloid leukemia, relapsed acute myeloid leukemia